Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.

S'inscrire

EOLS Evolus Inc

13,10

0,00 (0,00%)

Avant marché

Dernière mise à jour : 10:00:00

Retardé de 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

05/13/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ VIKRAM MALIK

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Evolus (NASDAQ:EOLS)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024

Plus de graphiques de la Bourse Evolus

Evolus (NASDAQ:EOLS)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024

Plus de graphiques de la Bourse Evolus

Actualités Evolus Inc

Form S-8 - Securities to be offered to employees in employee benefit plans
Mercredi 6 Novembre 2024 ( il y a 4 semaines) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mercredi 6 Novembre 2024 ( il y a 4 semaines) • Edgar (US Regulatory)

Form 8-K - Current report
Mercredi 6 Novembre 2024 ( il y a 4 semaines) • Edgar (US Regulatory)

Evolus Reports Third Quarter 2024 Results
Mercredi 6 Novembre 2024 ( il y a 4 semaines) • Business Wire

Evolus to Participate in Stifel 2024 Healthcare Conference
Vendredi 1 Novembre 2024 ( il y a 1 mois) • Business Wire

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
Jeudi 31 Octobre 2024 ( il y a 1 mois) • Business Wire

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers
Mardi 29 Octobre 2024 ( il y a 1 mois) • Business Wire

Evolus to Report Third Quarter Financial Results on November 6, 2024
Mercredi 23 Octobre 2024 ( il y a 1 mois) • Business Wire

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Samedi 12 Octobre 2024 ( il y a 2 mois) • Business Wire

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Samedi 28 Septembre 2024 ( il y a 2 mois) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Samedi 7 Septembre 2024 ( il y a 3 mois) • Edgar (US Regulatory)

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024
Vendredi 6 Septembre 2024 ( il y a 3 mois) • Business Wire

Plus d'articles sur Evolus Inc

Societe Generale

JP Morgan Chase

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales